Clinical trials: Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy
Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy
Phase II Clinical Study of RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorectal Cancer
RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorectal Cancer
- Trial name
- NCT07895355
- Testing
- RC148 plus Telisotuzumab adizutecan, Telisotuzumab adizutecan plus Bevacizumab
- Where
- China
- Volunteers
- 412 people
- Sponsor
- RemeGen Co., Ltd.